Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 8,687 | 18,642 | 8,495 | 16,759 | 20,884 |
| Gross Profit | 8,687 | 18,642 | 8,495 | 16,759 | 20,884 |
| Operating Expenses | 29,999 | 28,446 | 96,844 | 34,906 | 32,951 |
| Operating Income | -21,312 | -9,804 | -88,349 | -18,147 | -12,067 |
| Other Income | 259 | 229 | 15,589 | -1,355 | -889 |
| Pre-tax Income | -21,053 | -9,575 | -72,760 | -19,502 | -12,956 |
| Income Tax | -2,884 | -562 | N/A | N/A | N/A |
| Net Income Continuous | -18,169 | -9,013 | -62,188 | -19,502 | -12,956 |
| Net Income | $-18,169 | $-9,013 | $-62,188 | $-19,502 | $-12,956 |
| EPS Basic Total Ops | -0.29 | -0.15 | -1.23 | -0.38 | -0.25 |
| EPS Basic Continuous Ops | -0.29 | -0.15 | -1.23 | -0.38 | -0.25 |
| EPS Diluted Total Ops | -0.29 | -0.15 | -1.23 | -0.38 | -0.25 |
| EPS Diluted Continuous Ops | -0.29 | -0.15 | -1.23 | -0.38 | -0.25 |
| EBITDA(a) | $-18,601 | $-7,677 | $-86,325 | $-15,862 | $-9,462 |